Skip to main content
. 2019 May 21;78(9):1215–1219. doi: 10.1136/annrheumdis-2018-215003

Figure 2.

Figure 2

Impact of joint and skin improvements on patient health-related quality of life as measured by EQ-5D VAS. Heat maps depict change from baseline in EQ-5D VAS at week 24, with a range from least improvement (blue) to greatest improvement (red). Joint and skin improvements measured by per cent improvements from baseline DAPSA and PASI scores at week 24, respectively. Patients with baseline psoriasis of ≥3% (A) and ≥10% BSA (B) are depicted in the left and right panels, respectively. BSA, body surface area; DAPSA, Disease Activity Index for Psoriatic Arthritis; EQ-5D, European Quality of Life-Five Dimensions; PASI, Psoriasis Area and Severity Index; VAS, Visual Analogue Score.